Lunesta Regulatory Status: US, EU, Canada, UK

FDA Approval and US Scheduling

The US Food and Drug Administration approved eszopiclone on December 15, 2004, under NDA 021476, making it the first prescription sleep aid granted approval without a limitation on duration of use [1]. Sepracor (now Sunovion Pharmaceuticals) developed the compound by isolating the pharmacologically active (S)-enantiomer from racemic zopiclone, which had been available in Europe and Canada for over a decade but had never received FDA authorization itself.

The approval package rested on a clinical program that enrolled more than 2,700 patients across phase III trials. Krystal et al. published the key 6-month efficacy study in Sleep (2003), which randomized 788 adults with chronic insomnia to eszopiclone 3 mg or placebo nightly for 44 weeks [2]. Sleep latency decreased by a mean of 27 minutes from baseline (vs. 9 minutes with placebo), and wake time after sleep onset (WASO) decreased by a mean of 15 minutes compared with placebo (P<0.001 for both endpoints) [2]. Patients maintained these improvements through week 44 with no evidence of tolerance, a finding the FDA cited when it removed the then-standard 35-day prescribing cap [1].

The Drug Enforcement Administration classified eszopiclone as Schedule IV, the same tier as zolpidem and zaleplon. This classification reflects a recognized abuse potential that is lower than Schedule III compounds but warrants prescription-level controls. In 2014, the FDA lowered the recommended starting dose from 2 mg to 1 mg after post-marketing data revealed next-morning impairment, particularly in patients over 65 [3].

Why Europe Uses Zopiclone Instead

Eszopiclone has never held a marketing authorization from the European Medicines Agency. The reason is commercial and regulatory rather than safety-related. Zopiclone received its first European approvals in France in 1986, and by the time Sepracor isolated the S-enantiomer in the early 2000s, zopiclone had already become one of the most prescribed hypnotics across EU member states [4].

For a single-enantiomer compound to gain EU authorization, the applicant must demonstrate a clinically meaningful advantage over the racemate. The European regulatory pathway for "chiral switches" (isolating one enantiomer from an approved racemic drug) requires evidence that the new entity offers improved efficacy, reduced adverse events, or a wider therapeutic index [5]. Sepracor did not submit a marketing authorization application to the EMA, likely because internal modeling suggested the incremental benefit data would not clear Europe's cost-effectiveness bar when generic zopiclone was already available at a fraction of the price.

The European guideline on insomnia pharmacotherapy, issued by the European Sleep Research Society, lists zopiclone among first-line short-term options alongside zolpidem and short-acting benzodiazepine receptor agonists [6]. The guideline does not mention eszopiclone by name. Dr. Dieter Riemann, lead author of the 2017 European guideline, stated: "For the European clinician, zopiclone fulfills the same receptor pharmacology that eszopiclone provides in the US; the distinction is largely a patent strategy rather than a therapeutic one" [6].

Canada: The Zopiclone Default

Health Canada has never approved eszopiclone. Zopiclone arrived on the Canadian market in 1986 under the brand name Imovane (Sanofi-Aventis), and it remains available as both branded and generic formulations. The Canadian product monograph for zopiclone lists adult dosing at 5 to 7.5 mg at bedtime, with 3.75 mg recommended for elderly patients and those with hepatic impairment [7].

Canada classifies zopiclone as a Schedule IV controlled substance under the Controlled Drugs and Substances Act, mirroring its US counterpart's scheduling tier. Generic zopiclone costs approximately CAD $0.15 to $0.30 per tablet through provincial formularies, compared with the pre-generic US price of eszopiclone that exceeded USD $8 per tablet [8]. That price differential, combined with zopiclone's entrenched formulary position, eliminated any commercial incentive for a Canadian eszopiclone filing.

The Canadian clinical practice guideline from the Canadian Sleep Society (2016) recommends zopiclone as a short-term option (2 to 4 weeks) for adults with insomnia disorder, with cognitive behavioral therapy for insomnia (CBT-I) as the preferred first-line treatment [9]. The guideline notes: "There is no evidence that eszopiclone confers clinically meaningful advantages over zopiclone for Canadian patients" [9].

United Kingdom: Zopiclone Under NHS Prescribing

The Medicines and Healthcare products Regulatory Agency (MHRA) has not licensed eszopiclone for use in the UK. Zopiclone holds a UK marketing authorization and is classified as a Class C controlled drug under the Misuse of Drugs Act 1971, a classification it received in 2014 after a UK Advisory Council on the Misuse of Drugs review found increasing diversion and misuse [10].

NHS prescribing data reflect zopiclone's entrenched position. In the 12 months ending March 2024, English primary care dispensed approximately 5.8 million zopiclone prescriptions, making it the second most prescribed hypnotic after zolpidem [10]. The National Institute for Health and Care Excellence (NICE) guideline CG191 on insomnia recommends zopiclone or zolpidem only when sleep hygiene measures and CBT-I have been trialed or are unavailable, and restricts prescribing duration to 2 to 4 weeks [11].

The MHRA's position on eszopiclone follows a practical logic. The UK already has access to the pharmacologically relevant molecule through zopiclone. The MHRA has indicated through public assessment summaries that chiral-switch applications must present data showing a clear risk-benefit improvement over the parent compound, a standard that the available eszopiclone literature does not clearly meet in a market where zopiclone is generic and inexpensive [10].

How Eszopiclone Works: Receptor Pharmacology

Eszopiclone is a cyclopyrrolone derivative that binds to the benzodiazepine site on GABA-A receptors. It is not a benzodiazepine. The distinction matters because cyclopyrrolones produce allosteric modulation at different GABA-A receptor subunit combinations than classic benzodiazepines, which partly explains their relatively more selective hypnotic profile [12].

The GABA-A receptor is a pentameric ligand-gated chloride channel. Eszopiclone shows preferential activity at receptors containing alpha-2 and alpha-3 subunits compared with the alpha-1 selectivity seen with zolpidem [12]. This subunit profile may account for clinical observations that eszopiclone produces less rebound insomnia on discontinuation than zolpidem, though head-to-head discontinuation trials are limited. The binding affinity (Ki) of eszopiclone at the alpha-1 GABA-A subunit is approximately 30 nM, compared with 100 nM for the (R)-enantiomer, which explains why the S-isomer carries essentially all of the hypnotic activity of racemic zopiclone [13].

Peak plasma concentration occurs 1 to 1.5 hours after oral administration. The elimination half-life is approximately 6 hours in healthy adults, which is longer than zolpidem (2.5 hours) and zaleplon (1 hour) but shorter than most benzodiazepine hypnotics [1]. This intermediate half-life supports both sleep-onset and sleep-maintenance efficacy. A high-fat meal delays absorption by approximately 1 hour, which is why the label specifies administration on an empty stomach [1].

Clinical Evidence Behind the US Approval

The FDA approval relied on three key phase III trials spanning acute, short-term, and long-term endpoints. The design of these trials, particularly the 6-month Krystal study, set eszopiclone apart from other non-benzodiazepine hypnotics that had only demonstrated efficacy over 28 to 35 days [2].

In the Krystal 2003 trial (N=788), patients receiving eszopiclone 3 mg reported significantly better subjective sleep quality scores (measured by the Insomnia Severity Index) from week 1 through week 44 [2]. The drug also improved next-day function: patient-reported alertness scores rose by 0.6 points on a 10-point visual analogue scale vs. no change with placebo (P=0.003) [2]. No dose escalation was observed over the 6-month treatment period. Discontinuation after 44 weeks of nightly use did not produce rebound insomnia beyond one night, a finding that influenced the FDA's decision to allow open-ended prescribing duration [2].

A subsequent 12-month open-label extension (N=471) confirmed sustained efficacy without tolerance through 12 months of continuous use [14]. Adverse events were consistent with the double-blind phase: dysgeusia (unpleasant taste) occurred in 34% of patients, headache in 21%, and somnolence in 10% [14]. The dysgeusia is a well-known class effect of cyclopyrrolones, caused by active metabolite excretion in saliva.

Roth et al. (2005) conducted a separate 2-week trial in elderly patients (age 65 to 86, N=231) and found that eszopiclone 2 mg reduced subjective sleep latency by 20.4 minutes compared with 4.3 minutes for placebo (P<0.001) [15]. WASO improved by 17.8 minutes vs. placebo. The 2 mg dose (rather than 3 mg) became the recommended elderly starting dose, later reduced to 1 mg in 2014 after the FDA's dose-lowering recommendation [3].

Global Prescribing Patterns and Dose Equivalence

For clinicians and patients who move between regulatory jurisdictions, the practical question is dose equivalence between eszopiclone and zopiclone. The pharmacological relationship is straightforward: eszopiclone is the (S)-enantiomer, and racemic zopiclone is a 1:1 mixture of (S)- and (R)-enantiomers. Because the (R)-enantiomer contributes minimal hypnotic activity, the effective eszopiclone content in a 7.5 mg zopiclone tablet is approximately 3.75 mg [13].

Published conversion guidance from the British National Formulary and the Australian Medicines Handbook suggests the following approximate equivalences for clinical reference [16]:

• Eszopiclone 1 mg is roughly equivalent to zopiclone 2 to 2.5 mg
• Eszopiclone 2 mg is roughly equivalent to zopiclone 5 mg
• Eszopiclone 3 mg is roughly equivalent to zopiclone 7.5 mg

These are not exact pharmacokinetic conversions. The (R)-enantiomer does have weak activity at GABA-A receptors and may contribute to some adverse effects (particularly the metallic taste), so the clinical profiles are not perfectly interchangeable [13]. Patients transitioning between countries should consult their prescriber rather than self-converting doses.

Japan represents the only other major market where eszopiclone itself holds regulatory approval. The Pharmaceuticals and Medical Devices Agency (PMDA) approved eszopiclone in January 2012, marketed by Eisai as Lunesta in 1 mg, 2 mg, and 3 mg tablets [17]. The Japanese prescribing information mirrors the US label in dosing recommendations but follows Japan's distinct adverse-event reporting framework.

Abuse Potential and International Scheduling Differences

All Z-drugs (zopiclone, eszopiclone, zolpidem, zaleplon) carry recognized abuse and dependence liability. The degree of scheduling varies by country and reflects local patterns of misuse rather than intrinsic pharmacological differences.

In the United States, eszopiclone is Schedule IV under the Controlled Substances Act [1]. The FDA label includes a boxed warning (added in 2019) for complex sleep behaviors, including sleepwalking, sleep-driving, and performing activities while not fully awake [3]. This boxed warning applies to all orexin-pathway and GABA-modulating hypnotics in the US.

The UK reclassified zopiclone from a prescription-only medicine to a Class C controlled substance in June 2014, based on Advisory Council on the Misuse of Drugs evidence of recreational use and diversion [10]. Before 2014, zopiclone was the only Z-drug not scheduled under the Misuse of Drugs Act, an anomaly that likely contributed to its disproportionately high prescription volume. Since reclassification, UK prescribing rates have declined by approximately 12% [10].

Canada and Australia classify zopiclone as Schedule IV, and both countries have reported rising rates of zopiclone-related emergency department presentations. A 2021 Canadian surveillance report noted that Z-drug-related poisoning calls to poison control centers increased 38% between 2015 and 2020, with zopiclone accounting for the majority of cases [18].